Pi3 Kinases

In this video, Aruna Padmanabhan, MD, discusses the evaluation of PI3K inhibitor combinations as first-line treatment for patients with metastatic breast cancer.

The FDA granted priority review to a new drug application for leniolisib to treat activated phosphoinositide 3-kinase delta syndrome in adults and adolescents aged 12 years and older, according to a Pharming Group press release.

Columbia University will award this year’s Louisa Gross Horwitz Prize to three scientists for their seminal contributions to understanding of the role the PI3 kinase pathway plays in cancer physiology and oncogenesis.